Literature DB >> 23907181

High mobility group box 1 in patients with 2009 pandemic H1N1 influenza-associated encephalopathy.

Hiroshi Momonaka1, Shunji Hasegawa2, Takeshi Matsushige1, Hirofumi Inoue1, Madoka Kajimoto1, Seigo Okada1, Kenji Nakatsuka3, Tsuneo Morishima4, Takashi Ichiyama1.   

Abstract

BACKGROUND: Patients with 2009 pandemic H1N1 influenza-associated encephalopathy (pIE) have been reported in Japan. The most common clinical symptoms of this condition are seizures and progressive coma with high-grade fever. We previously highlighted the cytokine profile of pIE; our results suggest that proinflammatory cytokines play an important role in the pathogenesis. High mobility group box 1 (HMGB1) protein is a late mediator of inflammation or sepsis. However, there are few reports regarding the serum and cerebrospinal fluid (CSF) levels of HMGB1 in pIE patients.
METHODS: We measured serum and CSF levels of HMGB1 in the following: pIE patients with poor outcomes, pIE patients without neurological sequelae, influenza patients without pIE, and control subjects.
RESULTS: Serum HMGB1 levels were significantly higher in pIE patients with poor outcomes compared to those without neurological sequelae. In contrast, there was no difference in CSF HMGB1 levels among all groups. Regarding pIE patients, we found a significant positive correlation between HMGB1 levels and IL-6 in the serum but not in the CSF.
CONCLUSIONS: Our results suggest that HMGB1 protein may be involved in the pathogenesis of pIE and that a high serum, but not CSF, level of inflammatory cytokines plays an important role in the severity of pIE.
Copyright © 2013 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  2009 Pandemic H1N1 influenza; Encephalopathy; HMGB1; IL-6

Mesh:

Substances:

Year:  2013        PMID: 23907181     DOI: 10.1016/j.braindev.2013.07.001

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  8 in total

Review 1.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

2.  Anti-high mobility group box-1 monoclonal antibody treatment provides protection against influenza A virus (H1N1)-induced pneumonia in mice.

Authors:  Nobuyuki Nosaka; Masato Yashiro; Mutsuko Yamada; Yosuke Fujii; Hirokazu Tsukahara; Keyue Liu; Masahiro Nishibori; Akihiro Matsukawa; Tsuneo Morishima
Journal:  Crit Care       Date:  2015-06-11       Impact factor: 9.097

3.  HMGB1/RAGE Signaling and Pro-Inflammatory Cytokine Responses in Non-HIV Adults with Active Pulmonary Tuberculosis.

Authors:  Grace Lui; Chun Kwok Wong; Margaret Ip; Yi Jun Chu; Irene M H Yung; Catherine S K Cheung; Lin Zheng; Judy S Y Lam; Ka Tak Wong; Winnie W Y Sin; Kin Wing Choi; Nelson Lee
Journal:  PLoS One       Date:  2016-07-19       Impact factor: 3.240

4.  Local and Systemic Immune Responses to Influenza A Virus Infection in Pneumonia and Encephalitis Mouse Models.

Authors:  Yoshiharu Nagaoka; Nobuyuki Nosaka; Mutsuko Yamada; Masato Yashiro; Yosuke Washio; Kenji Baba; Tsuneo Morishima; Hirokazu Tsukahara
Journal:  Dis Markers       Date:  2017-08-24       Impact factor: 3.434

5.  Serum High-Mobility-Group Box 1 as a Biomarker and a Therapeutic Target during Respiratory Virus Infections.

Authors:  Mira C Patel; Kari Ann Shirey; Marina S Boukhvalova; Stefanie N Vogel; Jorge C G Blanco
Journal:  mBio       Date:  2018-03-13       Impact factor: 7.867

6.  Transformation of urban mobility during COVID-19 pandemic - Lessons for transportation planning.

Authors:  Syed Masiur Rahman; Nedal Ratrout; Khaled Assi; Ibrahim Al-Sghan; Uneb Gazder; Imran Reza; Omer Reshi
Journal:  J Transp Health       Date:  2021-09-11

Review 7.  Endothelial Dysfunction, HMGB1, and Dengue: An Enigma to Solve.

Authors:  María-Angélica Calderón-Peláez; Carolina Coronel-Ruiz; Jaime E Castellanos; Myriam L Velandia-Romero
Journal:  Viruses       Date:  2022-08-12       Impact factor: 5.818

8.  The θ-defensin retrocyclin 101 inhibits TLR4- and TLR2-dependent signaling and protects mice against influenza infection.

Authors:  Daniel Prantner; Kari Ann Shirey; Wendy Lai; Wuyuan Lu; Alexander M Cole; Stefanie N Vogel; Alfredo Garzino-Demo
Journal:  J Leukoc Biol       Date:  2017-07-20       Impact factor: 4.962

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.